ArticleFrontiers in medicine2026
A sequential strategy of upfront radiofrequency ablation followed by endoscopic papillectomy for complex ampullary tumors.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endoscopic papillectomy (EP) is the first-line treatment for ampullary tumors, and radiofrequency ablation (RFA) as an alternative or adjunctive treatment. This study systematically analyzed EP's clinical outcomes and evaluated the feasibility and safety of a sequential RFA-first strategy for complex ampullary tumors. Methods: We retrospectively analyzed 132 patients treated with EP or RFA at Shenzhen People's Hospital from April 2018 to August 2024. Categorical variables were presented as frequencies (percentages), and continuous variables as mean ± Standard Deviation (SD). Binary logistic regression analyzed risk factors. Propensity score matching and analysis of variance (ANOVA) compared adverse events between treatments. Results: Initially, 123 of 132 patients underwent EP, while 9 received RFA as the initial treatment due to tumors >3 cm, peri-diverticular lesions, and intraductal invasive lesions. The technical success rate was 100%, and the overall short-term clinical success rate was 96.6%. Adverse events occurred in 20.5% of the patients. Tumor size was identified as a significant risk factor for adverse events such as postprocedural pancreatitis ( Conclusion: An upfront RFA strategy followed by staged EP or additional RFA may be a potentially feasible and safe method to reduce adverse events in select patients with complex ampullary tumors. However, long-term efficacy and late complication rates require further evaluation with extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.